Advanced

An emerging role for calcium sensitisation in the treatment of heart failure.

Erhardt, Leif RW LU (2005) In Expert Opinion on Investigational Drugs 14(6). p.659-670
Abstract
Heart failure occurs in 2 - 3% of the adult population in the developed world. With decompensation of cardiac function, haemodynamic stability can be achieved by using intravenous vasodilators, diuretics and inotropes. Unlike traditional inotropes, Ca2+, sensitisers enhance cardiac function without significantly increasing cardiac oxygen consumption, promoting arrhythmia or impairing lusitropy. The most promising drug in this new class is levosimendan, which has a unique dual mechanism; it enhances cardiac output through a Ca2+-dependent stabilisation of cardiac myofilaments and exhibits vasodilatory effects by opening ATP-dependent K+ channels. Clinical trials have demonstrated the beneficial haemodynamic effects of levosimendan, and... (More)
Heart failure occurs in 2 - 3% of the adult population in the developed world. With decompensation of cardiac function, haemodynamic stability can be achieved by using intravenous vasodilators, diuretics and inotropes. Unlike traditional inotropes, Ca2+, sensitisers enhance cardiac function without significantly increasing cardiac oxygen consumption, promoting arrhythmia or impairing lusitropy. The most promising drug in this new class is levosimendan, which has a unique dual mechanism; it enhances cardiac output through a Ca2+-dependent stabilisation of cardiac myofilaments and exhibits vasodilatory effects by opening ATP-dependent K+ channels. Clinical trials have demonstrated the beneficial haemodynamic effects of levosimendan, and prospective trials are currently underway to confirm its potential benefits on long-term prognosis. Updated guidelines from the European Society of Cardiology advise on how to incorporate levosimendan into care for patients who have acute heart failure. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
therapy, heart Failure, calcium sensitiser, clinical trials, inotropes, levosimendan, heart-failure
in
Expert Opinion on Investigational Drugs
volume
14
issue
6
pages
659 - 670
publisher
Ashley Publications
external identifiers
  • wos:000231215200007
  • pmid:16004594
  • scopus:21244451092
ISSN
1744-7658
DOI
10.1517/13543784.14.6.659
language
English
LU publication?
yes
id
66338815-c295-4a7e-8407-90563351bbb7 (old id 142257)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16004594&dopt=Abstract
date added to LUP
2007-07-18 16:20:26
date last changed
2017-01-01 04:34:01
@article{66338815-c295-4a7e-8407-90563351bbb7,
  abstract     = {Heart failure occurs in 2 - 3% of the adult population in the developed world. With decompensation of cardiac function, haemodynamic stability can be achieved by using intravenous vasodilators, diuretics and inotropes. Unlike traditional inotropes, Ca2+, sensitisers enhance cardiac function without significantly increasing cardiac oxygen consumption, promoting arrhythmia or impairing lusitropy. The most promising drug in this new class is levosimendan, which has a unique dual mechanism; it enhances cardiac output through a Ca2+-dependent stabilisation of cardiac myofilaments and exhibits vasodilatory effects by opening ATP-dependent K+ channels. Clinical trials have demonstrated the beneficial haemodynamic effects of levosimendan, and prospective trials are currently underway to confirm its potential benefits on long-term prognosis. Updated guidelines from the European Society of Cardiology advise on how to incorporate levosimendan into care for patients who have acute heart failure.},
  author       = {Erhardt, Leif RW},
  issn         = {1744-7658},
  keyword      = {therapy,heart Failure,calcium sensitiser,clinical trials,inotropes,levosimendan,heart-failure},
  language     = {eng},
  number       = {6},
  pages        = {659--670},
  publisher    = {Ashley Publications},
  series       = {Expert Opinion on Investigational Drugs},
  title        = {An emerging role for calcium sensitisation in the treatment of heart failure.},
  url          = {http://dx.doi.org/10.1517/13543784.14.6.659},
  volume       = {14},
  year         = {2005},
}